Montréal, Quebec, Canada The main department of described VC is located in the Montru00e9al. The venture was found in North America in Canada.
The typical case for the fund is to invest in rounds with 4-5 participants. Despite the T2C2 Capital, startups are often financed by Pitango Venture Capital, GeneChem, Canadian Medical Discoveries Fund. The meaningful sponsors for the fund in investment in the same round are Desjardins Venture Capital, Business Development Bank of Canada, Fonds de solidaritu00e9 FTQ. In the next rounds fund is usually obtained by VenGrowth Asset Management, Desjardins Venture Capital, Caisse de Depot et Placement du Quebec.
Among the various public portfolio startups of the fund, we may underline Enobia Pharma, Cytochroma, Interomex BioPharmaceuticals For fund there is a match between the country of its foundation and the country of its the most frequent investments - Canada. Among the most popular fund investment industries, there are Biopharma, Analytics. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund.
The top amount of exits for fund were in 2013. The real fund results show that this VC is 11 percentage points less often commits exit comparing to other companies. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in less than 2 investment rounds annually. The important activity for fund was in 2005. Opposing the other organizations, this T2C2 Capital works on 16 percentage points more the average amount of lead investments.
Related Funds
Funds with similar focus
| Fund Name | Location |
| 45J Ventures | - |
| Alcuin Capital Partners | England, London, United Kingdom |
| Beiyin Fengye | Beijing, China, Mentougou |
| Caracol Television | Buenaventura, Colombia, Valle del Cauca |
| Emulex | California, Costa Mesa, United States |
| Furui Caizhi Guquan Jijin | China, Jiangsu, Nanjing |
| Hudson Ventures | New York, New York, United States |
| Indian Dream Capital | - |
| Magna Investment | Seoul, Seoul-t'ukpyolsi, South Korea |
| MKaNN | - |
| Mount Sinai Ventures | New York, New York, United States |
| Nishi-Nippon City Bank | Fukuoka, Fukuoka Prefecture, Japan |
| Park Bench Capital | California, San Francisco, United States |
| Qianzhang Investment | China, Shanghai |
| Revolution Health | District of Columbia, United States, Washington |
| San Francisco 49ers | California, Santa Clara, United States |
| Sirius Venture Capital Pte Ltd | Central Region, Singapore, Singapore |
| Swallow Point Ventures | Pennsylvania, Pittsburgh, United States |
| Tri State Ventures | New York, New York, United States |
| Vantage Investment Management | Black River, Black River, Mauritius |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
| $30M | 25 Oct 2006 | Ile-de-France | |||
TransPharma Medical | $18M | 24 Jul 2006 | Israel, North District, Israel | ||
Topigen Pharmaceuticals | $4M | 10 Oct 2005 | Quebec | ||
BioAxone Therapeutic | $12M | 20 May 2005 | Canada, Manitoba, Canada | ||
Enobia Pharma | $15M | 18 Jan 2005 | Montreal, Quebec | ||
Chronogen | $13M | 26 Nov 2003 | Montreal, Quebec, Canada | ||
| $2M | 18 Dec 2001 | Kingston, Ontario | |||
Interomex BioPharmaceuticals | $4M | 05 Oct 2001 | Vancouver, British Columbia, Canada | ||
Quazal Technologies | $3M | 24 Feb 2000 | Montreal, Quebec, Canada |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
| $30M | 25 Oct 2006 | Ile-de-France | |||
TransPharma Medical | $18M | 24 Jul 2006 | Israel, North District, Israel | ||
Topigen Pharmaceuticals | $4M | 10 Oct 2005 | Quebec | ||
BioAxone Therapeutic | $12M | 20 May 2005 | Canada, Manitoba, Canada | ||
Enobia Pharma | $15M | 18 Jan 2005 | Montreal, Quebec | ||
Chronogen | $13M | 26 Nov 2003 | Montreal, Quebec, Canada | ||
| $2M | 18 Dec 2001 | Kingston, Ontario | |||
Interomex BioPharmaceuticals | $4M | 05 Oct 2001 | Vancouver, British Columbia, Canada | ||
Quazal Technologies | $3M | 24 Feb 2000 | Montreal, Quebec, Canada |
